AR071633A1 - Encapsulacion de agentes biologicamente activos - Google Patents
Encapsulacion de agentes biologicamente activosInfo
- Publication number
- AR071633A1 AR071633A1 ARP090101616A ARP090101616A AR071633A1 AR 071633 A1 AR071633 A1 AR 071633A1 AR P090101616 A ARP090101616 A AR P090101616A AR P090101616 A ARP090101616 A AR P090101616A AR 071633 A1 AR071633 A1 AR 071633A1
- Authority
- AR
- Argentina
- Prior art keywords
- biologically active
- organic phase
- emulsion
- hip
- aqueous phase
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title abstract 6
- 238000005538 encapsulation Methods 0.000 title 1
- 239000012074 organic phase Substances 0.000 abstract 8
- 239000008346 aqueous phase Substances 0.000 abstract 6
- 238000000034 method Methods 0.000 abstract 6
- 239000000839 emulsion Substances 0.000 abstract 5
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 239000000178 monomer Substances 0.000 abstract 4
- 229920000642 polymer Polymers 0.000 abstract 4
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 abstract 2
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical group [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 abstract 2
- 238000004090 dissolution Methods 0.000 abstract 2
- 230000002209 hydrophobic effect Effects 0.000 abstract 2
- 150000002500 ions Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000003960 organic solvent Substances 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 238000006116 polymerization reaction Methods 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 229960000800 cetrimonium bromide Drugs 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 238000000265 homogenisation Methods 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 238000002156 mixing Methods 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 239000012071 phase Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000000926 separation method Methods 0.000 abstract 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical group [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 abstract 1
- 230000003381 solubilizing effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5077508P | 2008-05-06 | 2008-05-06 | |
| US7417108P | 2008-06-20 | 2008-06-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR071633A1 true AR071633A1 (es) | 2010-06-30 |
Family
ID=40944671
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090101617A AR072359A1 (es) | 2008-05-06 | 2009-05-05 | Encapsulacion de agentes biologicamente activos |
| ARP090101618A AR071634A1 (es) | 2008-05-06 | 2009-05-05 | Nanoparticulas para encapsulacion de agentes biologicamente activos |
| ARP090101619A AR072668A1 (es) | 2008-05-06 | 2009-05-05 | Encapsulacion de agentes biologicamente activos |
| ARP090101616A AR071633A1 (es) | 2008-05-06 | 2009-05-05 | Encapsulacion de agentes biologicamente activos |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090101617A AR072359A1 (es) | 2008-05-06 | 2009-05-05 | Encapsulacion de agentes biologicamente activos |
| ARP090101618A AR071634A1 (es) | 2008-05-06 | 2009-05-05 | Nanoparticulas para encapsulacion de agentes biologicamente activos |
| ARP090101619A AR072668A1 (es) | 2008-05-06 | 2009-05-05 | Encapsulacion de agentes biologicamente activos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110064821A1 (enExample) |
| EP (2) | EP2271323A2 (enExample) |
| JP (1) | JP2011522792A (enExample) |
| KR (3) | KR20110010760A (enExample) |
| AR (4) | AR072359A1 (enExample) |
| CA (1) | CA2721241A1 (enExample) |
| CL (4) | CL2009001076A1 (enExample) |
| PE (4) | PE20091965A1 (enExample) |
| TW (4) | TW201012489A (enExample) |
| UY (4) | UY31808A (enExample) |
| WO (1) | WO2009135853A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102088963A (zh) * | 2008-05-06 | 2011-06-08 | 葛兰素集团有限公司 | 生物活性剂的囊封方法 |
| WO2013021353A1 (en) | 2011-08-11 | 2013-02-14 | Bar-Ilan University | Surface modified proteinaceous spherical particles and uses thereof |
| US10112988B2 (en) | 2012-01-09 | 2018-10-30 | Icb International, Inc. | Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide |
| US10112987B2 (en) * | 2012-01-09 | 2018-10-30 | Icb International, Inc. | Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide |
| JP6612333B2 (ja) * | 2014-05-30 | 2019-11-27 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | 高薬物負荷ポリ（アルキル２−シアノアクリレート）ナノカプセル |
| JP6651507B2 (ja) * | 2014-05-30 | 2020-02-19 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | 抗原結合性分子のナノ封入 |
| US20150359804A1 (en) * | 2014-06-12 | 2015-12-17 | Orbis Biosciences, Inc. | Extended-release drug delivery compositions |
| JP6554493B2 (ja) | 2014-06-24 | 2019-07-31 | ザ・トラスティーズ・オブ・プリンストン・ユニバーシティＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｐｒｉｎｃｅｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | 可溶性生物製剤、治療薬およびイメージング剤をカプセル化するためのプロセス |
| WO2019055539A1 (en) | 2017-09-12 | 2019-03-21 | Prudhomme Robert K | CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME |
| JP2021501753A (ja) * | 2017-11-03 | 2021-01-21 | ザ・トラスティーズ・オブ・プリンストン・ユニバーシティＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｐｒｉｎｃｅｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | 徐放性ナノキャリア製剤を形成するための疎水性イオン対化およびフラッシュナノ沈殿 |
| US12186436B2 (en) | 2018-07-19 | 2025-01-07 | The Trustees Of Princeton University | Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents |
| US11731099B2 (en) | 2018-07-20 | 2023-08-22 | The Trustees Of Princeton University | Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation |
| US20220031630A1 (en) * | 2018-09-13 | 2022-02-03 | The Brigham And Women's Hospital, Inc. | Nanoparticle formulations and methods of their use |
| US20200147032A1 (en) | 2018-11-14 | 2020-05-14 | Robert K. Prud'homme | Dihydromyricetin hot melt extrusion formulations and methods for forming them |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4833666A (en) | 1986-12-24 | 1989-05-23 | U.S. Philips Corporation | Disc-record player suitable for scanning disc of different types |
| FR2649321A1 (fr) * | 1989-07-07 | 1991-01-11 | Inst Nat Sante Rech Med | Compositions a base de derives nucleotidiques, leurs procedes de preparation, et leurs utilisations notamment en tant que compositions pharmaceutiques |
| FR2659554B1 (fr) * | 1990-03-16 | 1994-09-30 | Oreal | Composition pour le traitement cosmetique et/ou pharmaceutique des couches superieures de l'epiderme par application topique sur la peau et procede de preparation correspondant. |
| EP0683667A1 (en) * | 1993-02-15 | 1995-11-29 | Shield Research Limited | Polyalkylcyanoacrylate nanocapsules |
| DE59409568D1 (de) * | 1993-09-09 | 2000-11-30 | Schering Ag | Wirkstoffe und gas enthaltende mikropartikel |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9809839D0 (en) | 1998-05-09 | 1998-07-08 | Glaxo Group Ltd | Antibody |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US20030152636A1 (en) * | 2000-02-23 | 2003-08-14 | Nanopharm Ag | Method of treating cancer |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| AU2002354644C1 (en) * | 2001-07-10 | 2009-04-30 | Corixa Corporation | Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres |
| AR040778A1 (es) | 2002-08-06 | 2005-04-20 | Glaxo Group Ltd | Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina). |
| CA2531238C (en) | 2003-07-04 | 2015-02-24 | Affibody Ab | Polypeptides having binding affinity for her2 |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| KR20060129246A (ko) | 2003-12-05 | 2006-12-15 | 컴파운드 쎄라퓨틱스, 인크. | 타입 2 혈관 내피 성장 인자 수용체의 억제제 |
| JP2008513363A (ja) | 2004-09-14 | 2008-05-01 | ナノデル テクノロジーズ ゲーエムベーハー | ナノ粒子を含む送達媒体 |
| GB0525662D0 (en) | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Immunoglobulins |
| PL2177536T3 (pl) | 2006-03-30 | 2014-11-28 | Glaxo Group Ltd | Przeciwciała przeciwko peptydowi beta-amyloidu |
| EP1958957A1 (en) | 2007-02-16 | 2008-08-20 | NascaCell Technologies AG | Polypeptide comprising a knottin protein moiety |
| GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| BRPI0812398A2 (pt) | 2007-06-06 | 2019-09-24 | Domantis Ltd | domínio variável simples de imunoglobulina anti-vegf, antagonista anti-vegf, domínio variável simples de imunoglobulina resistente à protease, uso do antagonista vegf, método para a dispensação oral ou dispensação de um medicamento ao trato gi de um paciente ou ao pulmão ou tecido pulmonar ou olho de um paciente, dispositivo de dispensação pulmonar, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor, célula hospedeira, método para produzir polipeptídeo, composição farmacêutica, polipeptídeo, e, proteína de fusão |
-
2009
- 2009-05-05 KR KR1020107027449A patent/KR20110010760A/ko not_active Withdrawn
- 2009-05-05 US US12/991,556 patent/US20110064821A1/en not_active Abandoned
- 2009-05-05 UY UY0001031808A patent/UY31808A/es unknown
- 2009-05-05 CL CL2009001076A patent/CL2009001076A1/es unknown
- 2009-05-05 TW TW098114853A patent/TW201012489A/zh unknown
- 2009-05-05 AR ARP090101617A patent/AR072359A1/es not_active Application Discontinuation
- 2009-05-05 AR ARP090101618A patent/AR071634A1/es not_active Application Discontinuation
- 2009-05-05 TW TW098114851A patent/TW201012488A/zh unknown
- 2009-05-05 CL CL2009001077A patent/CL2009001077A1/es unknown
- 2009-05-05 TW TW098114867A patent/TW201006495A/zh unknown
- 2009-05-05 KR KR1020107027240A patent/KR20110010758A/ko not_active Withdrawn
- 2009-05-05 EP EP09742071A patent/EP2271323A2/en not_active Withdrawn
- 2009-05-05 PE PE2009000609A patent/PE20091965A1/es not_active Application Discontinuation
- 2009-05-05 AR ARP090101619A patent/AR072668A1/es not_active Application Discontinuation
- 2009-05-05 WO PCT/EP2009/055436 patent/WO2009135853A2/en not_active Ceased
- 2009-05-05 CL CL2009001080A patent/CL2009001080A1/es unknown
- 2009-05-05 CL CL2009001081A patent/CL2009001081A1/es unknown
- 2009-05-05 UY UY0001031809A patent/UY31809A/es unknown
- 2009-05-05 KR KR1020107027425A patent/KR20110015604A/ko not_active Withdrawn
- 2009-05-05 AR ARP090101616A patent/AR071633A1/es not_active Application Discontinuation
- 2009-05-05 PE PE2009000607A patent/PE20091829A1/es not_active Application Discontinuation
- 2009-05-05 TW TW098114865A patent/TW201012490A/zh unknown
- 2009-05-05 CA CA2721241A patent/CA2721241A1/en not_active Abandoned
- 2009-05-05 PE PE2009000606A patent/PE20091882A1/es not_active Application Discontinuation
- 2009-05-05 UY UY0001031807A patent/UY31807A/es unknown
- 2009-05-05 UY UY0001031810A patent/UY31810A/es unknown
- 2009-05-05 EP EP11192165A patent/EP2441447A1/en not_active Withdrawn
- 2009-05-05 PE PE2009000608A patent/PE20091964A1/es not_active Application Discontinuation
- 2009-05-05 JP JP2011507897A patent/JP2011522792A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110010758A (ko) | 2011-02-07 |
| PE20091964A1 (es) | 2010-01-09 |
| TW201006495A (en) | 2010-02-16 |
| CL2009001076A1 (es) | 2010-09-24 |
| CL2009001080A1 (es) | 2010-09-24 |
| TW201012489A (en) | 2010-04-01 |
| UY31808A (es) | 2009-12-14 |
| PE20091965A1 (es) | 2010-01-09 |
| KR20110015604A (ko) | 2011-02-16 |
| AR071634A1 (es) | 2010-06-30 |
| CA2721241A1 (en) | 2009-11-12 |
| UY31807A (es) | 2009-12-14 |
| AR072668A1 (es) | 2010-09-15 |
| PE20091882A1 (es) | 2009-12-24 |
| WO2009135853A2 (en) | 2009-11-12 |
| TW201012490A (en) | 2010-04-01 |
| TW201012488A (en) | 2010-04-01 |
| US20110064821A1 (en) | 2011-03-17 |
| JP2011522792A (ja) | 2011-08-04 |
| CL2009001077A1 (es) | 2010-09-24 |
| EP2441447A1 (en) | 2012-04-18 |
| AR072359A1 (es) | 2010-08-25 |
| EP2271323A2 (en) | 2011-01-12 |
| WO2009135853A3 (en) | 2011-05-12 |
| KR20110010760A (ko) | 2011-02-07 |
| UY31810A (es) | 2009-12-14 |
| PE20091829A1 (es) | 2009-12-12 |
| UY31809A (es) | 2009-12-14 |
| CL2009001081A1 (es) | 2010-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR071633A1 (es) | Encapsulacion de agentes biologicamente activos | |
| Yuan et al. | Improved transport and absorption through gastrointestinal tract by PEGylated solid lipid nanoparticles | |
| Wang et al. | Magnetically-driven drug and cell on demand release system using 3D printed alginate based hollow fiber scaffolds | |
| Wang et al. | Electrospun hydrophilic Janus nanocomposites for the rapid onset of therapeutic action of helicid | |
| Tikekar et al. | Fate of curcumin encapsulated in silica nanoparticle stabilized Pickering emulsion during storage and simulated digestion | |
| Falsini et al. | Sustainable strategies for large-scale nanotechnology manufacturing in the biomedical field | |
| CO2017001921A2 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
| PH12017502155A1 (en) | Formation of cyclosporin a/cyclodextrin nanoparticles | |
| WO2015152693A3 (ko) | 신규 이중 나선 올리고 rna 및 이를 포함하는 섬유증 또는 호흡기 질환의 예방 또는 치료용 약학조성물 | |
| WO2013093648A3 (en) | Method of producing lipid nanoparticles for drug delivery | |
| WO2007040469A3 (en) | Chloroquine coupled compositions and methods for their synthesis | |
| Win et al. | Engineering polymeric microparticles as theranostic carriers for selective delivery and cancer therapy | |
| Xie et al. | Solubility enhancement of curcumin via supercritical CO2 based silk fibroin carrier | |
| Sahu et al. | Nanographene oxide as a switch for CW/pulsed NIR laser triggered drug release from liposomes | |
| BRPI0518677A2 (pt) | produto sàlido, processos para a produÇço de um produto sàlido e para a produÇço de uma nanodispersço estabilizada ou micela carregada, lÍquido translécido, mÉtodo de tratamento mÉdico, e, dispositivo para a produÇço de formulaÇÕes sàlidas de agentes biologicamente ativos lÍquidos | |
| Sivamaruthi et al. | Mesoporous silica nanoparticles: types, synthesis, role in the treatment of alzheimer’s disease, and other applications | |
| Gul et al. | Human plasma derived exosomes: Impact of active and passive drug loading approaches on drug delivery | |
| Ahmed et al. | An update on strategies for optimizing polymer-lipid hybrid nanoparticle-mediated drug delivery: exploiting transformability and bioactivity of PLN and harnessing intracellular lipid transport mechanism | |
| WO2012018383A3 (en) | Interior functionalized hyperbranched dendron-conjugated nanoparticles and uses thereof | |
| Hamed et al. | Microneedles mediated-dermal delivery of Vitamin C: Formulation, characterization, cytotoxicity, and enhancement of stability | |
| GB2551453A (en) | Nanocarrier delivery system for hydrophobic substances | |
| Li et al. | Size-and dose-dependent body-wide organ transcriptomic responses to calcium phosphate nanomaterials | |
| CN103251555A (zh) | 一种用于癌症治疗的高载药量的棒形纳米药物的制备方法 | |
| Subramaniyan et al. | Nano-Revolution in Transdermal Drug Delivery: A Bibliographic Compilation of Vesicular System. | |
| CN104587467B (zh) | 一种包载icg的聚合物‑磷脂纳米颗粒及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |